Calcified Tissue International

, Volume 103, Issue 1, pp 1–4 | Cite as

Certainties and Uncertainties About Denosumab Discontinuation

  • Elena Tsourdi
  • M. Carola Zillikens

The subjects of optimal duration of osteoporosis treatment and consequences of stopping osteoporosis drugs have gained significant attention lately. The larger amount of data derives from the use of bisphosphonates, due to their longer existence in the armamentarium of osteoporosis therapy. It is an unequivocal fact that bisphosphonates, especially those with a greater binding affinity to hydroxyapatite such as alendronate and zoledronic acid, display a sustained effect on bone metabolism after their discontinuation. This effect is mirrored in a stabilization or very gradual decrease of bone mineral density (BMD) and a slow return of bone turnover markers (BTMs) towards baseline after cessation of bisphosphonate treatment [1, 2]. In this respect, bisphosphonates constitute an exception in the field of anti-osteoporosis drugs, since all other therapeutic agents have no persistent long-term effects on bone turnover after their discontinuation, as has been shown for estrogen replacement...



This work was supported by the MedDrive Starting Grant of TU Dresden to ET.

Compliance with Ethical Standards

Conflict of interest

Elena Tsourdi reported honoraria for lectures from Amgen. Carola Zillikens has received fees for lectures and participation in advisory boards from Amgen and Eli Lilly.


  1. 1.
    Ravn P, Weiss SR, Rodriguez-Portales JA et al (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate osteoporosis prevention study group. J Clin Endocrinol Metab 85:1492–1497PubMedGoogle Scholar
  2. 2.
    Bagger Y, Tankó LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301–307CrossRefPubMedGoogle Scholar
  3. 3.
    Tremollieres FA, Pouilles JM, Ribot C (2001) Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 12:385–390CrossRefPubMedGoogle Scholar
  4. 4.
    Naylor KE, Clowes JA, Finigan J, Paggiosi MA, Peel NF, Eastell R (2014) The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 46:592–597CrossRefGoogle Scholar
  5. 5.
    Meunier PJ, Roux C, Ortolani S et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663–1673CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555–1559CrossRefPubMedGoogle Scholar
  7. 7.
    Eisman JA, Bone HG, Hosking DJ et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242–251CrossRefPubMedGoogle Scholar
  8. 8.
    McClung MR, Chines A, Brown JP et al (2014) Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J Bone Mineral Res 29:S53Google Scholar
  9. 9.
    Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabet Endocrinol 5:513–523CrossRefGoogle Scholar
  10. 10.
    Miller PD, Wagman RB, Peacock M et al (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394–402CrossRefPubMedGoogle Scholar
  11. 11.
    Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980CrossRefPubMedGoogle Scholar
  12. 12.
    Brown JP, Dempster DW, Ding B et al (2011) Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. Bone 26:2737–2744Google Scholar
  13. 13.
    Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929–1930CrossRefPubMedGoogle Scholar
  14. 14.
    Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923–1925CrossRefPubMedGoogle Scholar
  15. 15.
    Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27:1917–1921CrossRefPubMedGoogle Scholar
  16. 16.
    Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical case report. J Clin Endocrinol Metab 102:354–358CrossRefPubMedGoogle Scholar
  17. 17.
    Polyzos SA, Terpos E (2016) Clinical vertebral fractures following denosumab discontinuation. Endocrine 54:271–272CrossRefPubMedGoogle Scholar
  18. 18.
    Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291–1296CrossRefPubMedGoogle Scholar
  19. 19.
    Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190–198CrossRefPubMedGoogle Scholar
  20. 20.
    Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17CrossRefPubMedGoogle Scholar
  21. 21.
    Meier C, Uebelhart B, Aubry-Rozier B et al (2017) Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly 147:w14484PubMedGoogle Scholar
  22. 22.
    Dempster DW (2000) The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 15:20–23CrossRefPubMedGoogle Scholar
  23. 23.
    McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27:1677–1682CrossRefPubMedGoogle Scholar
  24. 24.
    Anastasilakis AD, Yavropoulou MP, Makras P (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677–683CrossRefPubMedGoogle Scholar
  25. 25.
    Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int. PubMedCrossRefGoogle Scholar
  26. 26.
    Lamy O, Gonzalez-Rodriguez E (2018) Underestimation of vertebral fractures after denosumab discontinuation. J Bone Miner Res 33:547CrossRefPubMedGoogle Scholar
  27. 27.
    Saag KG, Wagman RB, Geusens P et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabet Endocrinol. CrossRefGoogle Scholar
  28. 28.
    Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-Up). Bone 98:54–58CrossRefPubMedGoogle Scholar
  29. 29.
    McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporosis Int 28:1723–1732CrossRefGoogle Scholar
  30. 30.
    Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371–374CrossRefPubMedGoogle Scholar
  31. 31.
    Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 10:3067–3068CrossRefGoogle Scholar
  32. 32.
    Horne AM, Mihov B, Reid IR (2018) Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif Tissue Int. CrossRefPubMedGoogle Scholar
  33. 33.
    Grey A, Bolland MJ, Horne A et al (2017) Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ 189:E1130–E1136CrossRefGoogle Scholar
  34. 34.
    Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28:2701–2705CrossRefPubMedGoogle Scholar
  35. 35.
    Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. PubMedCrossRefGoogle Scholar
  36. 36.
    Anastasilakis AD, Tournis S, Yavropoulou MP, Polyzos SA, Makras P (2018) Multiple vertebral fractures following denosumab discontinuation: are we exaggerating? Calcif Tissue Int. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes and Metabolic Bone Diseases, Department of Medicine IIITechnische Universität Dresden Medical CenterDresdenGermany
  2. 2.Center for Healthy AgingTechnische Universität Dresden Medical CenterDresdenGermany
  3. 3.Bone Center, Department of Internal MedicineErasmus MCRotterdamThe Netherlands

Personalised recommendations